超声引导经皮微波消融治疗起源于尾状叶的肝细胞癌：一项初步临床研究。

Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study.

机构信息

Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

出版信息

J Cancer Res Ther. 2021 Jul;17(3):764-770. doi: 10.4103/jcrt.JCRT_1851_20.

DOI:10.4103/jcrt.JCRT_1851_20

PMID:34269311

Abstract

OBJECTIVE

This study aimed to evaluate the efficacy, feasibility, and tolerability of ultrasound (US)-guided percutaneous microwave ablation (MWA) for treating hepatocellular carcinoma (HCC) originating in the caudate lobe.

MATERIALS AND METHODS

The treatment and survival parameters of 32 patients with HCC in the caudate lobe, who met the inclusion criteria and had received US-guided percutaneous MWA in our department from November 2010 to October 2015, were retrospectively analyzed. Imaging examination (contrast-enhanced computed tomography or magnetic resonance) 1 month after MWA was used to evaluate the efficacy of US-guided MWA.

RESULTS

Thirty-two patients underwent percutaneous MWA for caudate lobe HCC. The average tumor size was 3.42 ± 0.27 (range: 1-6.8) cm. The initial complete ablation (CA) rate was 87.5% (28/32), and the total CA rate was 96.88% (31/32). Furthermore, the median length of hospitalization was 4 days (range: 2-10 days), and no major complication was observed in this study. The overall survival rates were 87.5%, 50%, and 28.13% at 1, 2, and 3 years, respectively. The progression-free survival after MWA was 93.75%, 53.15%, and 28.13% at 6, 12, and 18 months, respectively.

CONCLUSIONS

US-guided percutaneous MWA was a safe and effective treatment. It is a promising alternative therapy for HCC originating in the caudate lobe.

摘要

目的

本研究旨在评估超声引导经皮微波消融（MWA）治疗尾状叶肝癌（HCC）的疗效、可行性和耐受性。

材料与方法

回顾性分析 2010 年 11 月至 2015 年 10 月我科符合纳入标准并接受超声引导经皮 MWA 治疗的 32 例尾状叶 HCC 患者的治疗和生存参数。MWA 后 1 个月行影像学检查（增强 CT 或磁共振）评估超声引导 MWA 的疗效。

结果

32 例患者接受了经皮 MWA 治疗尾状叶 HCC。平均肿瘤大小为 3.42±0.27（范围：1-6.8）cm。初始完全消融（CA）率为 87.5%（28/32），总 CA 率为 96.88%（31/32）。此外，中位住院时间为 4 天（范围：2-10 天），本研究未观察到重大并发症。总体生存率分别为 1、2 和 3 年时的 87.5%、50%和 28.13%。MWA 后无进展生存率分别为 6、12 和 18 个月时的 93.75%、53.15%和 28.13%。